EUVIMEDEUVIMED entdecken
Multizentrische Studie

Ruxolitinib for life-threatening corticosteroid-refractory hypereosinophilic syndrome: A multicenter case series

Clothilde Gros, Julien Rohmer, Guillaume Lefèvre, Julie Abraham, Julie Bardol, Quentin Bodard, Safia Chebrek, Nicolas Duployez, Stanislas Faguer, Benjamin Fournier, Mathieu Gerfaud-Valentin, Antoine Gaillet und 12 weitere

Clinical Immunology · 2026-10 · 287 · 110751

DOI: 10.1016/j.clim.2026.110751 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Immunology, 2026-10. Verfasst von Clothilde Gros und 23 weiteren Autor:innen. Beteiligte Einrichtung: Université de Versailles St Quentin-en-Yvelines, National Reference Center for Hypereosinophilic Syndromes (CEREO), Department of Internal Medicine, …. Hauptthemen laut MEDLINE: Pyrazoles, Hypereosinophilic Syndrome, Adrenal Cortex Hormones, Janus Kinase Inhibitors. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Life-threatening hypereosinophilic syndrome (HES) is a rare medical emergency with limited therapeutic options in corticosteroid-refractory cases. Preliminary reports suggest that Janus kinase inhibitors may be beneficial in eosinophil-associated disorders, including HES. We conducted a nationwide multicenter retrospective study to assess ruxolitinib. Thirteen patients with severe acute HES and organ- or life-threatening involvement were included, most requiring intensive care, with massive baseline absolute eosinophil counts (AEC, median 45 × 109/L) and major involvement including eosinophilic myocarditis, ischemic strokes, and vascular thromboses. Ruxolitinib was initiated after a median of 7 days of corticosteroids. A rapid decline in absolute eosinophil counts was observed after initiation of ruxolitinib, with hematologic response rates of 54%, 85%, and 92% at Days 7, 14, and 30. Clinical improvement was observed across organ systems. Adverse events were manageable, although three deaths occurred during follow-up, only one of which occurred on ruxolitinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesHypereosinophilic SyndromeAdrenal Cortex HormonesJanus Kinase InhibitorsHumansPyrimidinesNitrilesFemaleMaleMiddle AgedRetrospective StudiesAdultAgedEosinophilsTreatment OutcomeMyocarditis

Stichwörter der Autor:innen

Corticosteroid-refractoryEosinophiliaHypereosinophilic syndromeJanus kinase inhibitorsMyocarditisRuxolitinib

Substanzen

ruxolitinibPyrazolesPyrimidinesNitrilesAdrenal Cortex HormonesJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Université de Versailles St Quentin-en-Yvelines, National Reference Center for Hypereosinophilic Syndromes (CEREO), Department of Internal Medicine, Clinical Immunology and Hematology, Foch Hospital, Suresnes, France.
  • University of Lille, National Reference Center for Hypereosinophilic Syndromes (CEREO); Immunology Institute, Department of Internal Medicine, University Hospital of Lille, INSERM, U1286 - INFINITE - Institute for Trans…
  • Department of Hematology, University Hospital of Limoges, Limoges, France.
  • Department of Hematology, University Hospital Saint Eloi, Montpellier, France.
  • Department of Internal Medicine, Hospital of Angoulême, Angoulême, France.
  • Department of Hematology, Hospital of Avignon, Avignon, France.

Zitieren

APA

Gros, C., Rohmer, J., Lefèvre, G., Abraham, J., Bardol, J., Bodard, Q., Chebrek, S., Duployez, N., Faguer, S., Fournier, B., Gerfaud-Valentin, M., Gaillet, A., Guilpain, P., Heiblig, M., Huang, F., Jalaber, E., Le Calvez, B., Legendre, P., Rizzo, D., …, & Groh, M. (2026). Ruxolitinib for life-threatening corticosteroid-refractory hypereosinophilic syndrome: A multicenter case series. Clinical Immunology, 287, 110751. https://doi.org/10.1016/j.clim.2026.110751

Vancouver

Gros C, Rohmer J, Lefèvre G, Abraham J, Bardol J, Bodard Q, et al. Ruxolitinib for life-threatening corticosteroid-refractory hypereosinophilic syndrome: A multicenter case series. Clinical Immunology. 2026;287:110751. doi:10.1016/j.clim.2026.110751

BibTeX
@article{Gros2026,
  author = {Gros, Clothilde and Rohmer, Julien and Lefèvre, Guillaume and Abraham, Julie and Bardol, Julie and Bodard, Quentin and Chebrek, Safia and Duployez, Nicolas and Faguer, Stanislas and Fournier, Benjamin and Gerfaud-Valentin, Mathieu and Gaillet, Antoine and Guilpain, Philippe and Heiblig, Mael and Huang, Florent and Jalaber, Elie and Le Calvez, Baptiste and Legendre, Paul and Rizzo, David and Roche-Lestienne, Catherine and Theron, Alexandre and Thomas, Caroline and Kahn, Jean-Emmanuel and Groh, Matthieu},
  title = {Ruxolitinib for life-threatening corticosteroid-refractory hypereosinophilic syndrome: A multicenter case series},
  journal = {Clinical Immunology},
  year = {2026},
  volume = {287},
  pages = {110751},
  doi = {10.1016/j.clim.2026.110751}
}
Kostenlos starten →